FLT3 and acute myeloid leukemia: In conclusion, for non-transplant eligible intermediate- to adverse-risk FLT3-ITD–positive AML patients, maintenance therapy with sorafenib combined with the ITI regimen during post-chemotherapy remission effectively suppresses MRD conversion, prevents relapse, prolongs survival, and is associated with minimal adverse reactions and good tolerability.